期刊
BRITISH JOURNAL OF BIOMEDICAL SCIENCE
卷 74, 期 4, 页码 193-197出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/09674845.2017.1334740
关键词
Contrast-induced nephropathy; cystatin-C; beta(2)-microglobulin; dual-label time-resolved fluorescence immunoassay
资金
- National Natural Science Foundation of China [81270286, 81500520]
- Science and Technology Planning Project of Guangdong Province [2015A030302037]
- Guangdong Cardiovascular Institute
- Guangdong Cardiovascular Institute's Guangdong Provincial Cardiovascular Clinical Medicine Research Fund [2009X41]
- Clinical Translational Research Project from Guangdong General Hospital [2015zh01]
Background: Contrast media is widely used in clinical diagnostic and interventional procedures, but may cause damage to the kidney, that is, contrast-induced nephropathy. This study was to establish a dual-label time-resolved fluorescence immunoassay (TRFIA) for the simultaneous determination of renal function markers cystatin-C (Cys-C) and beta(2)-microglobulin (beta(2)-MG) for the early diagnosis and follow-up surveillance of contrast-induced nephropathy. Methods: A sandwich immunoassaywas used to detect the concentration of Cys-C, and the competitive immunoassay was used to detect the concentration of beta(2)-MG in 50 samples of urine. The performance of this dual-label TRFIA was evaluated and compared with commercial assays. Results: The sensitivity for Cys-C detection was 1.26 ng/ml, the average recovery was 99.36%; The sensitivity for beta(2)-MG detection was 2.13 ng/ml, the average recovery was 100.18%. Bland-Altman analysis showed that the dual-label TRFIA method and the commercial kits had a good agreement, suggesting they can be used interchangeably in clinical urine analysis. Conclusion: The present dual-label TRFIA has high sensitivity, specificity and accuracy in clinical sample analysis. This method can be used for the early diagnosis and follow-up surveillance of the contrast-induced nephropathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据